Pregabalin Capsule
Product Images NDC 70518-2525

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2525). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 75mg 70518 2525 00

Pregabalin 75 mg oral capsule label from RemedyRepack Inc. The label indicates a quantity of 90 capsules per package. The drug is classified as Schedule C-V and marked RX only. Manufacturer information shows Novadoz Pharmaceuticals LLC, Piscataway, NJ. Storage and handling directions are included, referencing the package insert for use details.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical formula panel showing the calculation for creatinine clearance (CLCr). The formula is CLCr = [(140 - age in years) × weight in kg] / [72 × serum creatinine in mg/dL], with a multiplier of 0.85 for female patients. This panel likely appears in the drug prescribing or pharmacokinetic information.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg three times a day compared to placebo. The graph illustrates greater improvement with higher doses of Pregabalin over placebo.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier type plot showing percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares two groups: one treated with Pregabalin 100 mg three times a day (dashed line) and the other with placebo (dotted line). The Pregabalin group shows a higher percent of patients improved across various levels of pain improvement compared to placebo.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A Kaplan-Meier curve chart showing the percent of patients improved by percent improvement in pain from baseline for Pregabalin dosed two times a day at 75 mg, 150 mg, and 300 mg, compared to a placebo. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline. Four lines depict the treatment effects for each dose and the placebo group.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

Kaplan-Meier plot showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph illustrates the distribution of pain improvement levels among the three treatment arms.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing the percent of patients improved by percent improvement in pain from baseline for Pregabalin at doses of 100 mg and 50 mg three times a day compared to placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents the percent of patients improved (0 to 100%). Three curves are plotted: 100 mg (dashed line), 50 mg (solid line), and placebo (dotted line).*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

Bar chart showing responder rates (%) from two studies, Study E1 and Study E3. Study E1 compares placebo and pregabalin doses of 50 mg, 150 mg, 300 mg, and 600 mg per day (all BID), with responder rates increasing from 14% for placebo to 51% at 600 mg/day. Study E3 compares placebo and pregabalin 600 mg/day dosed BID and TID, with responder rates of 9%, 43%, and 49%, respectively. Study group sizes (N) are noted below each bar.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line chart depicting seizure reduction as median percent change from baseline versus dose in mg/day. Four data series represent different dosing schedules labeled as Stukly E1BID, E2BID, E3BID, and E3TID. The graph includes p-values indicating statistical significance at various doses, showing increased seizure reduction with higher doses.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph illustrating percent of patients improved versus percent improvement in pain from baseline, comparing placebo and Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg. The graph shows distinct curves for each treatment group, with percent of patients improved decreasing as pain improvement increases.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing Pregabalin and placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR, from 0% to 100%, and the x-axis shows time in days from 0 to 180. The solid line represents Pregabalin and the dashed line represents placebo, illustrating the percentage of subjects without LTR over time for each group.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 12 using a BOCF method. The graph displays two curves: one for Pregabalin and one for placebo, showing a higher percentage of subjects improved with Pregabalin compared to placebo across most improvement thresholds.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing percent of subjects improved versus percent improved from baseline to week 16 using Baseline Observation Carried Forward (BOCF). The graph has two lines: a solid line for Pregabalin and a dotted line for placebo, showing a higher percent improvement for Pregabalin across the range.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin, showing its molecular arrangement with labeled functional groups including an amino group (NH2), carboxyl group (COOH), and isobutyl side chain. This diagram represents the active ingredient in the Pregabalin 75 mg oral capsule by RemedyRepack Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.